

|                                                                                                                                                                                                                                             |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|
| (51) International Patent Classification <sup>6</sup> :<br>G01N 33/58, 33/532, 33/543, C12Q 1/68                                                                                                                                            |  | A1                                                                                                                                                                                                                                                                                                                                                                                                                                                | (11) International Publication Number: <b>WO 95/24649</b>         |
|                                                                                                                                                                                                                                             |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                   | (43) International Publication Date: 14 September 1995 (14.09.95) |
| (21) International Application Number: PCT/GB95/00521                                                                                                                                                                                       |  | <b>(81) Designated States:</b> AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG). |                                                                   |
| (22) International Filing Date: 10 March 1995 (10.03.95)                                                                                                                                                                                    |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                   |
| (30) Priority Data:<br>9404709.9 11 March 1994 (11.03.94) GB                                                                                                                                                                                |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                   |
| (71) Applicant (for all designated States except US): MULTILYTE LIMITED [GB/GB]; 3rd floor, 63 Lincoln's Inn Fields, London WC2A 3LW (GB).                                                                                                  |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                   |
| (72) Inventor; and<br>(73) Inventor/Applicant (for US only): EKINS, Roger, Philip [GB/GB]; Multilyte Limited, Dept. of Molecular Endocrinology, University College and Middlesex, School of Medicine, Mortimer Street, London W1N 8AA (GB). |  |                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                   |
| (74) Agents: MEWBURN, Ellis et al.; York House, 23 Kingsway, London WC2B 6HP (GB).                                                                                                                                                          |  | <b>Published</b><br><i>With international search report.</i>                                                                                                                                                                                                                                                                                                                                                                                      |                                                                   |

The diagram illustrates a DNA microarray with two spots, SPOT 1 and SPOT 2, separated by a dashed line. Each spot contains a grid of DNA sequences. SPOT 1 shows sequences with labels 10, 12, 14, 16, and 18. SPOT 2 shows sequences with labels 20 and 22. Arrows indicate the binding of probes to specific sequences.

**SPOT 1**

Sequences in SPOT 1 (from top to bottom):

- Sequence 1: C A G T G T A
- Sequence 2: T T T A T G G
- Sequence 3: T T T A T G G
- Sequence 4: T T T A T G G
- Sequence 5: T T T A T G G
- Sequence 6: T T T A T G G
- Sequence 7: T T T A T G G
- Sequence 8: T T T A T G G
- Sequence 9: T T T A T G G
- Sequence 10: T T T A T G G
- Sequence 11: T T T A T G G
- Sequence 12: T T T A T G G
- Sequence 13: T T T A T G G
- Sequence 14: T T T A T G G
- Sequence 15: T T T A T G G
- Sequence 16: T T T A T G G
- Sequence 17: T T T A T G G
- Sequence 18: T T T A T G G

**SPOT 2**

Sequences in SPOT 2 (from top to bottom):

- Sequence 1: C A G T G T A
- Sequence 2: T T T A T G G
- Sequence 3: T T T A T G G
- Sequence 4: T T T A T G G
- Sequence 5: T T T A T G G
- Sequence 6: T T T A T G G
- Sequence 7: T T T A T G G
- Sequence 8: T T T A T G G
- Sequence 9: T T T A T G G
- Sequence 10: T T T A T G G
- Sequence 11: T T T A T G G
- Sequence 12: T T T A T G G
- Sequence 13: T T T A T G G
- Sequence 14: T T T A T G G
- Sequence 15: T T T A T G G
- Sequence 16: T T T A T G G
- Sequence 17: T T T A T G G
- Sequence 18: T T T A T G G
- Sequence 19: T T T A T G G
- Sequence 20: T T T A T G G
- Sequence 21: T T T A T G G
- Sequence 22: T T T A T G G

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |                                       |    |                          |
|----|--------------------------|----|---------------------------------------|----|--------------------------|
| AT | Austria                  | GB | United Kingdom                        | MR | Mauritania               |
| AU | Australia                | GE | Georgia                               | MW | Malawi                   |
| BB | Barbados                 | GN | Guinea                                | NE | Niger                    |
| BE | Belgium                  | GR | Greece                                | NL | Netherlands              |
| BF | Burkina Faso             | HU | Hungary                               | NO | Norway                   |
| BG | Bulgaria                 | IE | Ireland                               | NZ | New Zealand              |
| BJ | Benin                    | IT | Italy                                 | PL | Poland                   |
| BR | Brazil                   | JP | Japan                                 | PT | Portugal                 |
| BY | Belarus                  | KE | Kenya                                 | RO | Romania                  |
| CA | Canada                   | KG | Kyrgyzstan                            | RU | Russian Federation       |
| CF | Central African Republic | KP | Democratic People's Republic of Korea | SD | Sudan                    |
| CG | Congo                    | KR | Republic of Korea                     | SE | Sweden                   |
| CH | Switzerland              | KZ | Kazakhstan                            | SI | Slovenia                 |
| CI | Côte d'Ivoire            | LI | Liechtenstein                         | SK | Slovakia                 |
| CM | Cameroon                 | LK | Sri Lanka                             | SN | Senegal                  |
| CN | China                    | LU | Luxembourg                            | TD | Chad                     |
| CS | Czechoslovakia           | LV | Latvia                                | TG | Togo                     |
| CZ | Czech Republic           | MC | Monaco                                | TJ | Tajikistan               |
| DE | Germany                  | MD | Republic of Moldova                   | TT | Trinidad and Tobago      |
| DK | Denmark                  | MG | Madagascar                            | UA | Ukraine                  |
| ES | Spain                    | ML | Mali                                  | US | United States of America |
| FI | Finland                  | MN | Mongolia                              | UZ | Uzbekistan               |
| FR | France                   |    |                                       | VN | Viet Nam                 |
| GA | Gabon                    |    |                                       |    |                          |

BINDING ASSAY USING BINDING AGENTS WITH TAIL GROUPSField of the Invention

5       The present invention relates to binding assays using binding agents with tail groups, and in particular binding agents having oligonucleotide tail groups. These binding assays are useful in determining the concentration of analytes in liquid samples.

10

Background of the Invention

15       It is known to measure the concentration of an analyte, such as a drug or hormone, in a liquid sample by contacting the liquid sample with a binding agent immobilised on a solid support, the binding agent having binding sites specific for the analyte, separating the binding agent having analyte bound to it and measuring a value representative of the fraction of the binding sites of the binding agent that are occupied by the analyte. Typically, the concentration of the analyte in the liquid sample can then be determined by comparing the value representative of the fraction of the binding sites occupied by analyte against values obtained from a series of standard solutions containing known concentrations of analyte.

20       In the past, the measurement of the fraction of the binding sites occupied has usually been carried out by back-titration with a labelled developing reagent using either so-called competitive or non-competitive methods.

25       In the competitive method, the binding agent having analyte bound to it is back-titrated, either simultaneously or sequentially, with a labelled developing agent, which is typically a labelled version of the analyte or an anti-idiotypic antibody capable of recognising empty binding sites of the binding agent. The developing agent can be said to compete for the binding sites on the binding agent with the analyte whose concentration is being measured.

30  
35

The fraction of the binding sites which become occupied with the labelled analyte can then be related to the concentration of the analyte as described above.

5 In the non-competitive method, the binding agent having analyte bound to it is back-titrated with a labelled developing agent capable of binding to either the bound analyte or to the occupied binding sites on the binding agent. The fraction of the binding sites occupied by  
10 analyte can then be measured by detecting the presence of the labelled developing agent and, just as with competitive assays, related to the concentration of the analyte in the liquid sample as described above.

15 In both competitive and non-competitive methods, the developing agent is labelled with a marker to allow the developing agent to be detected. A variety of markers have been used in the past, for example radioactive isotopes, enzymes, chemiluminescent markers and fluorescent markers.

20 In the field of immunoassay, competitive assays have in general been carried out in accordance with design principles enunciated by Berson and Yalow, for instance in "Methods in Investigative and Diagnostic Endocrinology"  
25 (1973), pages 111-116. Berson and Yalow proposed that in the performance of competitive immunoassays, maximum sensitivity is achieved when an amount of binding agent is used to bind approximately 30-50% of a low concentration of the analyte to be detected. In non-competitive  
30 immunoassays, maximum sensitivity is generally thought to be achieved by using sufficient binding agent to bind close to 100% of the analyte in the liquid sample. However, in both cases immunoassays designed in accordance with these widely-accepted precepts require the volume of the sample  
35 to be known and the amount of binding agent used to be accurately known or known to be constant.

In International Patent Application WO 84/01031, I disclosed that the concentration of an analyte in a liquid sample can be measured by contacting the liquid sample with a small amount of binding agent having binding sites specific for the analyte. In this "ambient analyte" method, provided the amount of binding agent is small enough to have only an insignificant effect on the concentration of the analyte in the liquid sample, it is found that the fraction of the binding sites on the binding agent occupied by the analyte is effectively independent of the volume of the sample.

This approach is further refined in EP 304,202 which discloses that the sensitivity and ease of development in the assays in WO 84/01031 are improved by using an amount of binding agent less than  $0.1V/K$  moles located on a small area (or "microspot") on a solid support, where  $V$  is the volume of the sample and  $K$  is the affinity constant of the binding agent for the analyte. In both of these references, the fraction of the binding sites occupied by the analyte is measured using either a competitive or non-competitive technique as described above.

#### Summary of the Invention

There is continuing need to develop binding assays which have enhanced kinetics to allow assays to be carried out more quickly and easily. In addition, it would be desirable to provide a binding assay which the user of the assay can easily customise for the detection of different groups of analytes.

Accordingly, in a first aspect, the present invention provides a method of determining the concentrations of analytes in a liquid sample comprising:

(a) immobilising one or more capture agents on a solid support, each capture agent being capable of

specifically binding a given binding agent;

5 (b) contacting the liquid sample with one or more binding agents, each binding agent having binding sites specific for a given analyte so that a fraction of the binding sites become occupied by the analyte, and a tail group adapted to bind to a corresponding capture agent;

10 (c) contacting the liquid sample, either simultaneously or sequentially with the step (b), with the immobilised capture agents so that the binding agents become bound to their respective capture agents; and

(d) determining the fraction of the binding sites of a binding agent occupied by analyte to determine the concentration of the analyte in the liquid samples.

15 Accordingly, the present invention provides an assay in which the binding of the analytes takes place in the liquid phase, rather than at a surface of a solid substrate. This enhances the kinetics of the reaction between analyte and binding agent.

20 Thus, in one embodiment, contacting the liquid sample with the binding and capture agents simultaneously allows the assay to be carried out in a single step, eg using a single reaction vessel. Alternatively, sequential contact of the  
25 binding agent(s) and capture agent(s) may be preferred, especially where the liquid is serum or blood, and non-specific binding is an important source of error. In these cases, the binding agent can be first contacted with the liquid sample in a first vessel and then the sample  
30 transferred to a second vessel to allow the capture agent to bind the binding agent to the solid support.

35 In a second aspect, the present invention provides a method of immobilising one or more binding agents on a support, each binding agent having binding sites specific for a given analyte and a tail group adapted to bind to a capture agent, comprising:

(a) immobilising one or more capture agents on a support each capture agent being capable of binding to the tail group of a given binding agent and,

5 (b) contacting the binding agents with the support having the capture agents immobilised thereon so that the binding agents become specifically bound to their respective capture agents through their tail groups.

10 The above method can additionally comprise the step of attaching the tail groups to the binding agents prior to exposing them to the capture agents immobilised on the support.

15 Thus, it is possible for the user of the assay to customise binding agents for use in determining the concentration of different groups of analytes and using the customised binding agents in conjunction with a universal support having capture agents immobilised on it, to which the binding agents can individually bind by virtue of their  
20 tail groups.

In this aspect of the invention, the assay is carried out by exposing the support to a liquid sample after the binding agent(s) has or have become bound to the capture  
25 agent(s).

In either aspect, the present invention provides an assay in which the binding agent is indirectly linked to capture agent immobilised on the substrate via the tail group.

30 Preferably, the capture agent is an oligonucleotide sequence which can hybridise to a complementary sequence comprising the tail group of the binding agent. The oligonucleotides acting as capture agent or tail of the  
35 binding agent are sufficiently long to provide strong and specific hybridisation under the stringency conditions used in the assay. Typically, complementary oligonucleotides of

at least about 8 or 9 nucleotides in length are used. In a preferred embodiment, the oligonucleotides are preferably between 8 and 30 bases, more preferably between 16 and 20 bases, in length. However, the use of very long polynucleotides is not preferred as these can lead to a reduction in the specificity of binding different capture agents or to self hybridise, forming hairpin loops (double stranded regions). However, a suitable length and sequence of oligonucleotide for a set of assay conditions can readily be determined by those skilled in the art.

Conveniently, the binding agent is an antibody having binding sites specific for an analyte. Accordingly, when the capture agent on the support is exposed to the liquid phase binding agent, the binding agent becomes bound to the solid support. Alternatively, where the analyte is a nucleic acid sequence, the binding agent can be an oligonucleotide. Thus, in this embodiment, the binding agent has a first sequence capable of hybridising to the analyte and a second sequence acting as the tail group.

Preferably, a small amount of binding agent is used in accordance with the assays disclosed in WO 84/01031 or EP 304,202, so that the volume of the liquid sample need not be known. Thus, the amount of binding agent should be sufficiently small so that it does not significantly affect the ambient concentration of the analyte in the liquid sample. Typically, the use of an amount of binding agent which binds less than 5% of the analyte is preferred. However, the use of a smaller amount of binding agent, eg to bind 2% or 1% of the analyte, further reduces the disturbance to the ambient concentration of the analyte and helps to minimise the error in determining the analyte concentration.

Where the assay is conducted in accordance with EP 304,202 using less than 0.1V/K moles of binding agent, the affinity



constant (K) for the binding of analyte to binding agent is measured in accordance with normal practice. This means the value of the affinity constant used to determine how much binding agent constitutes 0.1V/K moles is the value that is obtained under the conditions (eg reactants, time of incubation, pH, temperature etc) that are used in the assay.

Preferably, each capture agent is used in excess to bind substantially all of a given binding agent. This maximises the assay sensitivity and ensures that when the amount of binding agent used needs to be known or known to be constant, the user of the assay can be confident that substantially all of a binding agent used in an assay becomes bound to its capture agent on the support.

Preferably, molecules of capture agent are immobilised on a support at discrete locations, eg as microspots. This allows the concentration of a plurality of different analytes to be simultaneously determined using a plurality of different capture agents at a series of locations on the support. Where the capture agent(s) is or are immobilised as microspots, the sensitivity of the assay can be improved immobilising the capture agent at high density, thereby improving the signal-to-noise ratio (see for example our co-pending application PCT/GB94/02814). Assuming sample volumes of the order of 0.1-1.0 ml, the microspots preferably have an area less than 1mm<sup>2</sup> and a final surface density of binding agent between 1000 and 100000 molecules/ $\mu$ m<sup>2</sup>.

Alternatively, a given capture agent can be immobilised on a support at a plurality of locations so that a series of measurements of the concentration of an analyte can be made simultaneously.

Preferably, the fraction of the binding sites occupied by

the analyte is detected using developing agents in a competitive and/or non-competitive method as described above. The developing agents are capable of binding to occupied or unoccupied binding sites of the binding agent or to bound analyte and are labelled to enable bound developing agent to be detected. Preferably, the developing agents are labelled antibodies.

The markers can be radioactive isotopes, enzymes, chemiluminescent markers or fluorescent markers. The use of fluorescent dye markers is especially preferred as the fluorescent dyes can be selected to provide fluorescence of an appropriate colour range (excitation and emission wavelength) for detection. Fluorescent dyes include coumarin, fluorescein, rhodamine and Texas Red. Fluorescent dye molecules having prolonged fluorescent periods can be used, thereby allowing time-resolved fluorescence to be used to measure the strength of the fluorescent signal after background fluorescence has decayed. Latex microspheres containing fluorescent or other markers, or bearing them on their surface can also be employed in this context. The signals from the markers can be measured using a laser scanning confocal microscope.

Alternatively, other high specific activity labels such as chemiluminescent labels can be used. In the case of chemiluminescent labels, the signals from different chemiluminescent labels used to mark binding agent or developing agent can be simultaneously detected using, for example a charge-coupled device (CCD).

The binding agent (or a proportion of it) can conveniently be labelled, eg with a fluorophor. In accordance with the method set out in EP 271,974, this means that it is not necessary for the user of the assay to know the amount of binding agent or to know that it is constant. This is because the ratio of the signals from the binding agent and

the signal indicating the fraction of the binding sites of the binding agent occupied by analyte is dependent on the fraction of the sites of the binding agent occupied by the analyte, but is independent of the total amount of binding agent present.

Alternatively, if the user of the assay knows the volume of the sample, a larger amount of binding agent can be used so that the assay is not operating under ambient analyte conditions. This allows the concentration of the analyte to be determined using one label on the developing agent and either knowing the amount of binding agent is constant or labelling it with a second marker so that the amount is known.

In a variant of this approach (described in our co-pending application PCT/GB94/00013), two labelled developing agents can be used, a first capable of specifically binding to unoccupied binding sites of the binding agent and a second capable of binding to occupied binding sites or bound analyte. Thus, the signal from either marker is representative of the fraction of the binding sites occupied by analyte, while the sum of the signals is representative of the total amount of binding agent used.

This method can also avoid the necessity of knowing that a constant amount of binding agent is used as variations in the amount of binding agent immobilised can readily be corrected for. Under these circumstances, the sample volume  $v$  must either be known or constant. This can be seen from the following formula show how the signals from two labelled developing agents relates to the concentration of analyte in a sample.

Let the signal emitted by the label marking the developing agent directed against occupied binding agent binding sites be given by  $S_o$ ,

and the signal emitted by the label marking the developing agent directed against unoccupied binding agent binding sites be given by  $S_u$ ,

5 and let the constants relating the respective signals to occupied and unoccupied sites be  $\epsilon_o$  and  $\epsilon_u$  respectively, and  $K$  = the effective equilibrium constant governing the reaction between the analyte and binding agent.

10 Then, if the analyte concentration in a sample is given by  $Y$ ,

$$Y = (S_o/\epsilon_o) [\epsilon_u/(KS_u) + 1/v]$$

15 Assuming  $v$  is known, this equation contains two unknown constants,  $\epsilon_o$  and  $\epsilon_u/K$ . By determining the signals  $S_o$  and  $S_u$  for a series of known analyte concentrations, these constants can be determined, and unknown analyte concentrations estimated from corresponding determinations of  $S_o$  and  $S_u$ . Thus, the assay need not work under ambient analyte conditions.

20 Under ambient analyte conditions, the term  $1/v$  becomes negligible, and  $S_o/S_u$  is proportional to the ambient analyte concentration.

25 In a first kit aspect, the present invention provides a kit for determining the concentrations of one or more analytes in a liquid sample in a method as described above, the kit comprising:

30 (a) a solid substrate having attached thereto at a plurality of locations capture agent capable of specifically binding a binding agent;

(b) one or more binding agents, each binding agent having binding sites specific for an analyte, and a tail group adapted to bind one or more capture agents; and

35 (c) one or more developing agents having markers capable of binding to occupied binding agent binding sites or analyte bound to binding agent or unoccupied binding

agent binding sites.

In a second kit aspect, the present invention provides a kit for customising an assay for the determination of the concentration of one or more analytes comprising:

(a) one or more tail groups, each tail group being for attachment to a binding agent;

(b) a solid substrate having attached thereto at a plurality of locations one or more capture agents capable of specifically binding to a tail group;

wherein the user of the assay attaches the tail groups to the binding agents, thereby providing binding agents which can be used in conjunction with the solid substrate to which the capture agents are attached in a method as described above.

#### Description of the Drawings

A preferred embodiment of the present invention will now be described with reference to the accompanying schematic drawings in which:

Figure 1 shows an assay to detect two analytes in a liquid sample using two species of capture agent and two species of binding agent, the capture agent immobilised at two microspots;

Figure 2 shows the assay of figure 1 in which the capture agent has become bound to the binding agent;

Figure 3 shows a non-competitive method of determining the occupancy of the binding agent using a second labelled antibody; and,

Figure 4 shows a graph of signal plotted against TSH concentration from the experimental example below.

#### Detailed Description

Figures 1 to 3 show a binding assay in which two species of binding agent 2,4 having binding sites specific for

different analytes 6,8 are used. Each binding agent 2,4 comprises an antibody 10,14 provided with an oligonucleotide tail group 12,16. The oligonucleotide tail groups have different nucleotide sequences, the sequences being complementary to one of the sequences of capture agents 18,20, immobilised on a solid support 22 in the form of microspots. In this example, the oligonucleotides are 8 nucleotides long.

In the assay, the two analytes 6,8 in the sample are exposed to binding agents 2,4 so that a fraction of the analytes 6,8 become bound to the antibodies 10,14. As this reaction occurs in the liquid phase, the kinetics of the reaction between the antibodies 10,14 and the analytes (antigens) 6,8 are optimised.

Simultaneously or sequentially with the initial antibody/analyte reaction, the liquid sample and binding agent are exposed to the solid support 22 having capture agents 18,20 immobilised on it. This allows the nucleotide sequences 12,16 of the binding agents 2,4 to bind to the complementary sequences of the capture agents 18,20 immobilised on the support 22. This is shown in Figure 2. However, the capture agents 16,18 are generally used in excess to ensure that substantially all the binding agent 10,14 is bound to the support 22. Thus, in figures 2 and 3, one molecule of capture agent 28 is left unoccupied.

The fraction of the binding sites of the binding agents 2,4 can then be determined using a conventional back-titration technique. Thus, in Figure 3 labelled antibodies 24,26 are used in a non-competitive technique to mark the presence of occupied binding agents 2,4 respectively. As the antibodies 24,26 are labelled with markers (not shown) a fraction of the binding sites of the binding agents 2,4 can then be determined. This in turn allows the concentration of the analytes in the liquid sample to be found, eg by

reference to results obtained using a series of solutions of known analyte concentration.

5 The assay shown in Figures 1 to 3 can be adapted to measure the concentration of any pair of analytes using the same solid support 22 having capture agents 18,20 immobilised on it. This can be done by providing binding agent suitable for binding an analyte with an oligonucleotide tail group 12,16 so that the binding agents will specifically bind to 10 one of the microspots 18,20. Thus, it is envisaged that the user of the assay will be able to customise his or her binding agent for use with a universal array of microspots.

#### Example

15

#### Reagents:

- 1) Mouse IgG (monoclonal anti-TSH) from the Scottish Antibody Production Unit (SAPU).
- 20 2) Rabbit IgG, goat anti-mouse IgG (whole molecule) and goat anti-rabbit IgG (whole molecule) antibodies from Sigma.
- 25 3) Sulfate Fluospheres, 0.1µm diameter, yellow/green fluorescent (ex 490; em 515nm) and Sulfate Fluospheres, 0.1µm diameter, red fluorescent (ex 580; em 605nm) from Molecular Probes.
- 30 4) Oligonucleotides from Oswell DNA Service:
  - a) CACACACACACACACA with 5'-biotin modification (poly-CA)
  - b) GTGTGTGTGTGTGTGTGT with 5'-phosphorothioate modification (poly-GT)
  - 35 c) GAGAGAGAGAGAGAGA with 5'-biotin modification (poly-GA)
  - d) CTCTCTCTCTCTCTCTCT with 5'-phosphorothioate

## modification (poly-CT)

- 5) Sulfo-LC-SPDP {sulfosuccinimidyl 6-[3'-(2-pyridyldithio)-propionamido]hexanoate} from Pierce.
- 6) PD10 columns and Sephadex G200 from Pharmacia.
- 7) RIA grade Bovine Serum Albumin (BSA), Tween20, sodium azide, di-sodium hydrogen orthophosphate anhydrous, sodium di-hydrogen orthophosphate, EDTA and Trizma from Sigma
- 8) Avidin DX from Vector Laboratories
- 9) Centricon-30 and Centriprep-30 concentrators from Amicon
- 10) Thyroid stimulating hormone (TSH) from NIH USA

Adsorption of Anti-Mouse IgG and Anti-Rabbit IgG Antibodies to Sulfate FluoSpheres

- 1) A 0.5ml aliquot of 2% (10mg), 0.1 $\mu$ m yellow/green FluoSpheres was added to 2mg of goat anti-mouse IgG antibody dissolved in 0.5ml 0.1M phosphate buffer, pH7.4.
- 25 A 0.5ml aliquot of 2% (10mg), 0.1 $\mu$ m red FluoSpheres was added to 2mg of goat anti-rabbit IgG antibody dissolved in 0.5ml 0.1M phosphate buffer, pH7.4. Both preparations were shaken overnight at room temperature.
- 2) The two preparations were centrifuged for 10min at 8°C in a MSE High-Spin 21 Ultra-centrifuge.
- 3) Each pellet was dispersed in 2ml of 1% BSA in phosphate buffer, shaken for 1 hour at room temperature and centrifuged as above.
- 4) Each pellet was dispersed in 2ml of 0.5% Tween20 in



phosphate buffer, shaken for 30min at room temperature and centrifuged as above.

5) Each pellet was dispersed in 2ml of phosphate buffer and centrifuged as above.

6) Each pellet was dispersed in 2ml of phosphate buffer and centrifuged as above.

7) Each pellet was dispersed in 2ml of 1% BSA containing 0.1% sodium azide and stored at 4°C.

#### Conjugation of Mouse Monoclonal IgG and Rabbit IgG to Oligonucleotides

1) 3mg of sulpho-LC-SPDP was added to 4.6mg of mouse anti-TSH monoclonal or rabbit IgG dissolved in 1ml of PBS/EDTA and shaken for 30min at room temperature.

2) The activated antibodies were separated from unreacted SPDP on PD10 columns. The samples were eluted with PBS/EDTA and 0.5ml fractions collected.

3) The fractions from the first peak containing the activated antibody were pooled and concentrated using a Centricon-30 concentrator to approximately 10µl.

4) 100nM of 5'-phosphorothioate modified poly-GT oligonucleotide was added to 14.8nM of the activated mouse monoclonal IgG. 58.3nM of 5'-phosphorothioate modified poly-CT oligonucleotide was added to 8.7nM of the activated rabbit IgG. Both preparations were made up to 1ml with PBS/EDTA and shaken overnight at room temperature.

5) The oligonucleotide conjugated mouse and rabbit IgG preparations were separated from unreacted oligonucleotides on a Sephadex G200 column (1.5 x 45cm). The samples were

eluted with PBS/EDTA and 2ml fractions collected.

- 5 6) The fractions from the first peak containing the oligonucleotide conjugated antibody were pooled and concentrated using a Centriprep-30 concentrator to approximately 500µl and stored at 4°C.

10 **To Demonstrate That a Mixture of Oligonucleotide-Conjugated Antibodies Would Hybridize Only With Complementary Oligonucleotide Deposited on a Solid-Phase as Microspots**

- 15 1) Dynatech black Microfluor microtitre wells were coated with 50µl of avidin-DX in 0.1M bicarbonate buffer, pH 8.5 and at a concentration of 5µg/ml for 5min at room temperature.

- 20 2) After washing with 0.01M phosphate buffer, the avidin coated microtitre wells were blocked with 200µl of 1% BSA for 1 hour at room temperature and washed again with the same buffer and dried.

- 25 3) A 0.25µl droplet of each of the two 5'-biotin modified poly-CA and poly-GA oligonucleotides in 0.1% BSA and at a concentration of 0.025nM/ml were deposited on opposite sides of avidin coated microtitre wells and allowed to react for 30min under a moist atmosphere. The droplets were then aspirated and the microtitre wells washed with phosphate buffer.

- 30 4) A 50µl aliquot of Tris-HCl assay buffer containing 0.25µg/ml each of the poly-GT-conjugated mouse monoclonal IgG and poly-CT-conjugated rabbit IgG was added to all but the control microtitre wells (50µl of assay buffer containing unconjugated mouse and rabbit IgG was added to  
35 the control wells instead), shaken for 1 hour under a moist atmosphere and washed with phosphate buffer containing 0.05% Tween20.

- 5) A 200µl aliquot of Tris-HCl assay buffer containing 0.3µg/ml goat anti-mouse IgG antibody conjugated yellow/green FluoSpheres and 0.6µg/ml goat anti-rabbit IgG antibody conjugated red FluoSpheres was added to all microtitre wells, shaken for 1 hour at room temperature, washed with phosphate-Tween20 buffer and scanned with a confocal laser scanning microscope equipped with an Argon/Krypton laser.

## 10 Results

Excitation: 488DF10

Emission: 525DF35

|    |               |                                |
|----|---------------|--------------------------------|
| 15 | <u>Sample</u> | <u>Yellow/Green<br/>Signal</u> |
|----|---------------|--------------------------------|

|         |          |
|---------|----------|
| Control | 13.3±0.5 |
|---------|----------|

|    |                                                     |            |
|----|-----------------------------------------------------|------------|
| 20 | Avidin---B-Poly-CA---Poly-GT-Mouse<br>IgG microspot | 100.9±10.9 |
|----|-----------------------------------------------------|------------|

|                                                      |          |
|------------------------------------------------------|----------|
| Avidin---B-Poly-GA---Poly-CT-Rabbit<br>IgG microspot | 16.9±0.3 |
|------------------------------------------------------|----------|

25

Excitation: 568DF10

Emission: 585EFLP

|    |               |                   |
|----|---------------|-------------------|
| 30 | <u>Sample</u> | <u>Red Signal</u> |
|----|---------------|-------------------|

|         |          |
|---------|----------|
| Control | 22.0±0.2 |
|---------|----------|

|                                                     |          |
|-----------------------------------------------------|----------|
| Avidin---B-Poly-CA---Poly-GT-Mouse<br>IgG microspot | 24.0±0.4 |
|-----------------------------------------------------|----------|

|    |                                                      |          |
|----|------------------------------------------------------|----------|
| 35 | Avidin---B-Poly-GA---Poly-CT-Rabbit<br>IgG microspot | 99.8±2.7 |
|----|------------------------------------------------------|----------|

### Conclusions

(1) The poly-GT oligonucleotide tagged mouse IgG hybridized only with complementary biotinylated poly-CA but not non-complementary biotinylated poly-GA oligonucleotide microspots deposited on the same microtitre well.

(2) The poly-CT oligonucleotide tagged rabbit IgG hybridized only with complementary biotinylated poly-GA but not non-complementary biotinylated poly-CA oligonucleotide microspots deposited on the same microtitre well.

### **To Demonstrate Antigen Binding of the Oligonucleotide Tagged Antibody Microspots**

1) Dynatech black Microfluor microtitre wells were coated with 50µl of avidin-DX in 0.1M bicarbonate buffer, pH 8.5 and at a concentration of 5µg/ml for 5min at room temperature.

2) After washing with 0.01M phosphate buffer, the avidin coated microtitre wells were blocked with 200µl of 1% BSA for 1 hour at room temperature and washed again with the same buffer and dried..

3) A 0.25 droplet of 5'-biotin modified poly-CA oligonucleotide in 0.1% BSA and at a concentration of 0.025nM/ml was deposited on each of the avidin coated microtitre wells and allowed to react for 30min under a moist atmosphere. The droplets were then aspirated and the microtitre wells washed with phosphate buffer.

4) A 50µl aliquot of Tris-HCl assay buffer containing 0.25µg/ml of the poly-GT-conjugated anti-TSH mouse monoclonal IgG was added to the microtitre wells, shaken for 1 hour under a moist atmosphere and washed with phosphate buffer containing 0.05% Tween20.

5) A 200 $\mu$ l aliquot of TSH standards in Tris-HCl assay buffer (0, 0.1, 0.3 & 1.0 $\mu$ U/ml) was added to triplicate wells and incubated for 1 hour at room temperature and washed with phosphate-Tween20 buffer.

5

6) A 200 $\mu$ l aliquot of 50 $\mu$ g/ml anti-TSH developing antibody conjugated yellow/green sulfate FluoSpheres was added to all microtitre wells, shaken for 1 hour at room temperature, washed with phosphate-Tween20 buffer and scanned with a confocal laser scanning microscope equipped with an Argon/Krypton laser.

10

#### Results and Conclusion

The poly-GT oligonucleotide tagged anti-TSH mouse monoclonal IgG was fully functional as demonstrated by the successful generation of a standard curve when it was used as binding antibody deposited on the solid-phase via biotinylated complementary poly-CA oligonucleotide coupled to avidin coated microtitre wells (see figure 4).

15

20

**CLAIMS:**

1. A method for determining the concentration of one or more analytes in a liquid sample comprising:

5 (a) immobilising one or more capture agents on a solid support, each capture agent being capable of specifically binding a given binding agent;

(b) contacting the liquid sample with one or more binding agents, each binding agent having binding sites  
10 specific for a given analyte so that a fraction of the binding sites become occupied by the analyte, and a tail group adapted to bind to a corresponding capture agent;

(c) contacting the liquid sample, either simultaneously or sequentially with the step (b), with the immobilised capture agents so that the binding agents  
15 become bound to their respective capture agents; and

(d) determining a value representative of the fraction of the binding sites of a given binding agent occupied by an analyte whereby to determine the  
20 concentration of the analyte in the liquid sample.

2. A method of immobilising one or more binding agents on a support, each binding agent having binding sites specific for a given analyte and a tail group adapted to bind to a capture agent, comprising:  
25

(a) immobilising one or more capture agents on a support each capture agent being capable of binding to the tail group of a given binding agent and,

(b) contacting the binding agents with the support having the capture agents immobilised thereon so that the  
30 binding agents become specifically bound to their respective capture agents through their tail groups.

3. A method according to claim 2 wherein the method  
35 additionally comprises the step of attaching the tail groups to the binding agents prior to exposing them to the capture agents immobilised on the support.

4. A method according to any one of claims 1 to 3 wherein the capture agents are oligonucleotides having sequences which can hybridise to a complementary sequence on the tail group of the corresponding binding agent.

5. A method according to claim 4 wherein the oligonucleotides are between 8 and 30 bases long.

5. A method according to any one of the preceding claims wherein the binding agent is an antibody having binding sites specific for an analyte.

6. A method according to any one of the preceding claims wherein a small amount of each binding agent is used so that the ambient concentration of the analyte for which the binding agent is specific is not significantly disturbed.

7. A method according to claim 6 wherein the small amount of binding agent is less than  $0.1V/K$  moles, where  $V$  is the volume of the sample and  $K$  is the effective affinity constant for the analyte binding to the binding agent.

8. A method according to any one of the preceding claims wherein each capture agent is used in excess to bind substantially all of a given binding agent.

9. A method according to any one of the preceding claims wherein the capture agent(s) are immobilised on a support at discrete locations.

10 A method according to claim 9 wherein the discrete locations are microspots.

11. A method according to any one of the preceding claims wherein a given capture agent is immobilised on the support at a plurality of locations so that a series of

measurements of the concentration of a given analyte can be made simultaneously.

5 12. A method according to any one of the preceding claims wherein the value representative of the fraction of the binding sites occupied by the analyte is determined using developing agents in a competitive and/or non-competitive method, the developing agents being labelled with markers.

10 13. A method according to claim 12 wherein the marker are fluorescent or chemiluminescent markers.

14. A kit for determining the concentrations of one or more analytes in a liquid sample in a method according to  
15 any one of claims 1 to 13, the kit comprising:

(a) a solid substrate having attached thereto at a plurality of locations capture agent capable of specifically binding a given binding agent;

(b) one or more binding agents, each binding agent  
20 having binding sites specific for an analyte, and a tail group adapted to bind one or more capture agents; and

(c) one or more developing agents having markers capable of binding to occupied binding agent binding sites or analyte bound to binding agent or unoccupied binding  
25 agent binding sites.

14. A kit for customising an assay for the determination of the concentration of one or more analytes in a liquid sample, the kit comprising:

30 (a) one or more tail groups, each tail group being for attachment to a binding agent;

(b) a solid substrate having attached thereto at a plurality of locations one or more capture agents capable of specifically binding to a tail group;

35 wherein the user of the assay attaches the tail groups to the binding agents, thereby providing binding agents which can be used in conjunction with the solid substrate



23

to which the capture agents are attached in a method according to any one of claims 1 to 13.

5

1 / 3




Figure 1




Figure 2




Figure 3

3 / 3

**A Microspot Sandwich TSH Assay Using Solid-phased  
Anti-TSH Capture Antibody Tagged with Oligonucleotide**




Figure 4

## INTERNATIONAL SEARCH REPORT

Intern. Application No.

PCT/GB 95/00521

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 G01N33/58 G01N33/532 G01N33/543 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages                                                                                                                                                                             | Relevant to claim No. |
|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| X          | JOURNAL OF CLINICAL MICROBIOLOGY ,<br>vol. 27, no. 1, 1989 WASHINGTON DC USA,<br>pages 120-125,<br>R.P. VISCIDI ET AL. 'MONOCLONAL ANTIBODY<br>SOLUTION HYBRIDIZATION ASSAY FOR DETECTION<br>OF HUMAN IMMUNODEFICIENCY VIRUS NUCLEIC<br>ACIDS'<br>see figure 1 | 1-3                   |
| A          | EP-A-0 422 861 (IMPERIAL CHEMICAL<br>INDUSTRIES) 17 April 1991<br>cited in the application<br>see the whole document<br>---<br>-/--                                                                                                                            | 1-14                  |



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

14 June 1995

Date of mailing of the international search report

22.06.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Van Bohemen, C

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 95/00521

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages                                                                                                            | Relevant to claim No. |
|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| A          | NUCLEAR MEDICINE AND BIOLOGY,<br>vol. 21, no. 3, 1 March 1994 LONDON UK,<br>pages 495-521,<br>R. EKINS 'Immunoassays: current events in<br>immunoanalysis'<br>see the whole document<br>----- | 1-14                  |

**Information on patent family members**

PCT/GB 95/00521

Form PCT/ISA/210 (patent family annex) (July 1992)